The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1478
Racemic Amphetamine Sulfate (Evekeo) for ADHD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved racemic amphetamine sulfate (Evekeo – Arbor) for oral treatment of attention-deficit/hyperactivity disorder (ADHD) in children ≥3 years old. It was also approved for treatment of narcolepsy in patients ≥6 years old and for short-term treatment of obesity in patients ≥12 years old.

AMPHETAMINES FOR ADHD ― Amphetamines generally have been as effective as methylphenidate in decreasing overactivity, impulsivity, and inattention in children with ADHD. Some children who have not responded to methylphenidate may respond to an amphetamine, and vice versa. Dextroamphetamine, mixed amphetamine salts, and lisdexamfetamine dimesylate, an oral prodrug of dextroamphetamine, vary in their durations of action, but appear to be similar in efficacy.1 All stimulants used for treatment of ADHD are classified as schedule II controlled substances by ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Racemic Amphetamine Sulfate (Evekeo) for ADHD
Article code: 1478c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian